Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome

Completed · Not applicable

Conditions studied: Inflammatory Bowel Syndrome

In brief

This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).

Key facts

Study ID

NCT05482464

Run by

Oregon State University

People needed

15

Starts

2022-01-01

Expected to finish

2024-09-01

Last updated by the study team

2025-04-04

Who can join

Age: 18 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fluent in English
• IBS diagnosis with Rome IV criteria
• People who have a primary care provider

You may not qualify if…

• Lactose or milk protein intolerance
• Any known other gastrointestinal disease or disorder beyond IBS, or major gastrointestinal surgery
• Habitual use of laxatives or antacids
• Pregnant or nursing.
• Use of pre or probiotics within one month prior to the study
• Use of antibiotics within one month prior to the study

Where it is running

• Milam Hall, Room 001 — Corvallis, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.